JWH-260

JWH-260 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptors. It was developed by Dr. John W. Huffman and is part of the JWH series of synthetic cannabinoids. JWH-260 is primarily used in scientific research to study the endocannabinoid system and its effects on the body.

Chemical Structure and Properties

JWH-260 is a member of the naphthoylindole family of synthetic cannabinoids. Its chemical structure is characterized by a naphthyl group attached to an indole core, with a methanone bridge linking the two. The presence of a dimethylheptyl side chain contributes to its high affinity for cannabinoid receptors.

• Molecular Formula: C28H33NO3
• Molecular Weight: 431.57 g/mol
• Chemical Structure:

 * Indole core
 * Naphthyl group
 * Dimethylheptyl side chain

Pharmacology

JWH-260 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors. These receptors are part of the G protein-coupled receptor family and are involved in a variety of physiological processes, including pain sensation, mood regulation, and appetite.

• CB1 Receptor Affinity: High
• CB2 Receptor Affinity: Moderate

The activation of these receptors by JWH-260 can lead to effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. However, the specific effects and potency can vary significantly due to differences in receptor binding and activation.

Legal Status

The legal status of JWH-260 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. Researchers must obtain special licenses to study this compound legally.

Research Applications

JWH-260 is used in research to better understand the endocannabinoid system and its role in various physiological and pathological processes. Studies often focus on its effects on:

• Neurotransmission
• Pain management
• Appetite regulation
• Mood disorders

Safety and Toxicology

As with many synthetic cannabinoids, the safety profile of JWH-260 is not well-established. Potential risks include:

• Cardiovascular effects
• Psychiatric effects
• Addiction potential

Also see

• JWH-018
• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system